Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

Marked Improvement in Four Regions of Body Consistent with Overall PASI

Response in REMICADE-Treated Patients

SAN ANTONIO, Feb. 4 /PRNewswire/ -- Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) achieved a consistently high level of skin clearance in each of the four body regions (head, trunk, lower and upper extremities) as measured by the Psoriasis Area Severity Index (PASI). At week 10 of the analysis, which included nearly 1,500 subjects, 71 percent of patients receiving REMICADE 3 mg/kg and 79 percent of patients receiving REMICADE 5 mg/kg achieved a PASI 75, or at least a 75 percent improvement in the chronic inflammatory condition, compared with three percent of patients receiving placebo (both P < 0.001). Additionally, 39 percent and 52 percent of patients receiving REMICADE 3 mg/kg and 5 mg/kg, respectively, achieved a PASI 90, or nearly complete skin clearance, versus one percent of patients receiving placebo (both P < 0.001). Investigators reported these findings at the 66th Annual Meeting of the American Academy of Dermatology.

In September 2006, the U.S. Food and Drug Administration (FDA) approved REMICADE (5 mg/kg) for the treatment of chronic severe plaque psoriasis. Following an initial three infusion treatments (induction regimen), REMICADE is given once every eight weeks, or as few as six times a year.

"This analysis shows that treatment with REMICADE resulted in a consistently high level of clinical response in each quadrant of the body evaluated by PASI, and the results were consistent with patients' overall psoriasis improvement," said Alan Menter, MD, dermatologist, Baylor Research Institute, Dallas, and lead study investigator. "REMICADE remains an important advancement and biologic treatment option for a broad spectrum of patients with severe psoriasis."

According to f
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... Inc. (NASDAQ: CYBX ), a global leader in ... announced it will participate in the 33 rd  Annual ... San Francisco . Dan ... at 11:00 AM Pacific Time.  A live audio webcast of ... Relations link on the Cyberonics home page at www.cyberonics.com ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Group, Inc. (NYSE: HGR ) announced today that it ... March 31, 2011, on Thursday, April 28, 2011. The ... the quarter ended March 31, 2011 on Wednesday, April 27, 2011 ... these results is scheduled to begin at 9:00 a.m., EDT, on ...
... (Pink Sheets: IMJX ), today officially reported ... highlighted the key business accomplishment during the past fiscal ... 2010 demonstrated significant improvement from 2009, with total sales ... all of 2010, both a significant improvement over the ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces First Quarter 2011 Earnings Release Conference Call 2ImageXpres Posts OTC Markets 2010 Annual Report 2ImageXpres Posts OTC Markets 2010 Annual Report 3
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 “ SmileStix ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... to create personal stickers. , The old saying goes, “A ... lot of words that can describe a single image, because ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... strangulation game in 2005-2006 , , THURSDAY, Feb. 14 (HealthDay ... playing the "choking game" since 1995, a new government ... "pass out game," "scarf game," "space monkey" and other ... oneself or another with hands or some sort of ...
... Next Before Final Version is,Voted On, BETHESDA, Md., ... "national need" will include occupational,therapists if an agreement made ... AOTA staff worked fast and furiously to have the ... was able to have Representative Tom,Price of Georgia ask ...
... team of researchers was able to identify the location ... through analysis of genetic material (DNA) from members of ... from autosomal dominant juvenile cataract. The corresponding protein belongs ... molecules across cell mem-branes. Surprisingly, this genetic defect may ...
... , , THURSDAY, Feb. 14 (HealthDay News) -- A new ... found in the U.S.-banned insecticide DDT accelerates the growth ... in the open access journal Breast Cancer Research ... of a hormone that would otherwise help inhibit growth ...
... of the presidential nomination campaign, some candidates health care ... phrase socialized medicine has been used to attack health ... by the Harvard Opinion Research Program at the Harvard ... that Americans are split on whether a socialized medical ...
... available for all Minnesotans, MINNEAPOLIS, Feb. 14 ... such as a birthday or holiday as a "quit ... perfect day to,quit smoking for that special someone, and ... Services from ClearWay,Minnesota(SM)., Some romantic benefits of quitting, ...
Cached Medicine News:Health News:'Choking Game' Turned Deadly for 82 Youths 2Health News:'Choking Game' Turned Deadly for 82 Youths 3Health News:AOTA Gets Profession Addressed on House Floor in Federal Loan Repayment Bill 2Health News:New cataract gene discovered 2Health News:DDT Compound Speeds Breast Cancer Growth 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:QUITPLAN(R) Services Can Help Make Valentine's Day Smoke-Free 2Health News:QUITPLAN(R) Services Can Help Make Valentine's Day Smoke-Free 3
... The new E300 Corneal ... diverse range of clinical procedures ... Refractive Surgery and Contact Lens ... compact cone design, the E300 ...
Egg-Shaped Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be e...
... The S7 with Discrete Technology ... plus unmatched scaffolding. Proprietary Secure Technology ... proximal pillows that partially encapsulate the ... Discrete Technology is designed to minimize ...
Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
Medicine Products: